ホーム › 多発性骨髄腫 › オハイオ › Cleveland
Cleveland、OHにおける多発性骨髄腫の臨床試験
Clevelandとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
被験者募集中第3相
- Research Site, Cleveland
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
被験者募集中第2相
- University Hospitals Cleveland Medical Center, Cleveland
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
被験者募集中第2相
- Cleveland Clinic, Cleveland
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
被験者募集中第3相
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Main Campus, Cleveland
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
被験者募集中第3相
- Cleveland Clinic, Cleveland
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1/2相
- Research Site, Cleveland
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
被験者募集中第3相
- Cleveland Clinic, Cleveland
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
被験者募集中第3相
- MetroHealth Medical Center, Cleveland
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
被験者募集中第1相
- Cleveland Clinic - Taussig Cancer Institute, Cleveland
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
被験者募集中第3相
- Research Site, Cleveland
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
被験者募集中第3相
- Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
被験者募集中観察研究
- University Hospitals Seidman Cancer Center, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
被験者募集中観察研究健康なボランティア歓迎
- Cleveland Clinic, Cleveland
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
被験者募集中第1相
- Cleveland Clinic, Cleveland
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
被験者募集中第1/2相
- University Hospitals Cleveland, Cleveland
LMY-920 for Treatment of Relapsed or Refractory Myeloma
被験者募集中第1相
- University Hospitals Seidman Cancer Center, Cleveland
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Boston, MA42件の研究
- Atlanta, GA41件の研究
- Houston, TX38件の研究
- Durham, NC37件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- Rochester, MN24件の研究
- St. Louis, MO24件の研究
- Columbus, OH24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
Clevelandにおける他の研究
- 非小細胞肺癌43件の研究
- がん（全種類）36件の研究
- 乳がん35件の研究
- 前立腺がん34件の研究
- 心不全33件の研究
- 転移性癌30件の研究
- 卵巣がん30件の研究
- 肺がん26件の研究
- 大腸癌24件の研究
- 心血管疾患22件の研究
- 子宮内膜がん20件の研究
- 急性骨髄性白血病20件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。